Search

Your search keyword '"de Almeida-Neto, Cesar"' showing total 261 results

Search Constraints

Start Over You searched for: Author "de Almeida-Neto, Cesar" Remove constraint Author: "de Almeida-Neto, Cesar"
261 results on '"de Almeida-Neto, Cesar"'

Search Results

1. HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017.

2. 10-year analysis of human immunodeficiency virus incidence in first-time and repeat donors in Brazil.

3. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic.

5. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease.

6. Are different motivations and social capital score associated with return behaviour among Brazilian voluntary non-remunerated blood donors?

7. Prevalence of serologic markers of transfusion and sexually transmitted infections and their correlation with clinical features in a large cohort of Brazilian patients with sickle cell disease.

8. Quality of life in pre-adolescent children with sickle cell disease in Brazil.

9. Social and behavioral characteristics of male blood donors and their sexual partners: an analysis to define risk subsets.

10. Test seeking: are healthcare professionals referring people to blood centers for infections marker testing?

15. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

16. A randomized trial to evaluate the use of text messaging, letter, and telephone call reminders to improve return of blood donors with reactive serologic tests.

17. Obesity and ABO blood group: Is there an association?

18. Contribution of the Retrovirus Epidemiology Donor Study (REDS) to research on blood transfusion safety in Brazil

19. Response to Letters Regarding Article, “Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic, Trypanosoma cruzi–Seropositive Former Blood Donors”

20. Prevalence of serologic markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus

21. Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic Trypanosoma cruzi–Seropositive Former Blood Donors

22. Interdonation intervals and patterns of return among blood donors in Brazil

23. The impact of simple donor education on donor behavioral deferral and infectious disease rates in São Paulo, Brazil

25. Profile of blood donors with serologic tests reactive for the presence of syphilis in São Paulo, Brazil

26. Risk factors for human immunodeficiency virus infection among blood donors in Sao Paulo, Brazil, and their relevance to current donor deferral criteria

28. Factors Associated with Leg Ulcers in Adults with Sickle Cell Disease in Brazil

31. Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review

34. SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study

35. Author response: SARS-CoV-2 antibody dynamics in blood donors and COVID-19 epidemiology in eight Brazilian state capitals: A serial cross-sectional study

38. Improved detection of hepatitis C virus‐positive blood donors and determination of infection status.

39. Predicting SARS-CoV-2 variant spread in a completely seropositive population using semi-quantitative antibody measurements in blood donors

40. Additional file 2 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

41. Additional file 11 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

42. Additional file 7 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

43. Additional file 6 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

44. Additional file 3 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

45. Additional file 5 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

46. Additional file 4 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

47. Additional file 9 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

48. Additional file 8 of Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial

49. Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.

Catalog

Books, media, physical & digital resources